The new administration is likely to target the Affordable Care Act and America’s unfavorable corporate tax rate.
FDA inspection process holds up expected approvals for Aerie, Bausch + Lomb, Nicox, and Ocular Therapeutix.
The cyclosporine ophthalmic solution is being studied in a Phase III confirmatory trial in the US.
The product captured 16 percent of the dry eye market with $14 million in sales, Shire said.
The bottle uses less plastic than a package of single-use vials and is available for the same price.
The company told analysts that the dry eye market expanded significantly during the quarter.
The company said 100 surgeons have scheduled patients for implantation of the inlay.
Key takeaway message of 2016 meeting was companies and surgeons achieve more together.
Joerg Reinhardt said all options are open after the US-based eye care division failed to develop as expected.
Eye care segment contributed 47 percent of the company’s total revenues.
The company said the increase was driven by growth in sales volume of Alimera’s lead product, Iluvien.
The company launched its TECNIS Symfony lens during Q3-2016.
The company expects to announce topline data from Phase III trials of Fovista in combination with Lucentis for wet AMD in Q4-2016.
Company said its products have been used in an estimated
375 thousand ocular surgeries.
Revenues are expected to total $7.6 billion by 2021.
Recent court cases have backed manufacturers’ rights to share truthful information.
Job candidates find better pay and quicker hiring process at manufacturers.
Several companies are currently pursuing this technology, recognizing the need to address the continued challenges with daily eye drop regimens.
TruthinRx.org also will lobby Congress to make drug pricing more transparent.
You are not currently logged in.
©2017 Market Scope
Lost your Password